Neuroprotective effects of huperzine A - A natural cholinesterase inhibitor for the treatment of Alzheimer's disease

被引:121
|
作者
Wang, R [1 ]
Tang, XC [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
关键词
huperzine A; Alzheimer's disease; acetylcholinesterase; cholinesterase inhibitor; cognitive enhancer; neuroprotection; oxidative stress; beta-amyloid; amyloid precursor protein; cerebral ischemia; apoptosis; apoptotic-related gene; mitochondria; glutamate; NMDA receptor; potassium current;
D O I
10.1159/000085387
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Huperzine A (HupA), isolated from Chinese herb Huperzia serrata, is a potent, highly specific and reversible inhibitor of acetylcholinesterase. It has been found to reverse or attenuate cognitive deficits in a broad range of animal models. Clinical trials in China have demonstrated that HupA significantly relieves memory deficits in aged subjects, patients with benign senescent forgetfulness, Alzheimer's disease (AD) and vascular dementia (VD), with minimal peripheral cholinergic side effects compared with other AChEls in use. HupA possesses the ability to protect cells against hydrogen peroxide, beta-amyloid protein (or peptide), glutamate, ischemia and staurosporine-induced cytotoxicity and apoptosis. These protective effects are related to its ability to attenuate oxidative stress, regulate the expression of apoptotic proteins Bcl-2, Bax, P53 and caspase-3, protect mitochondria, and interfere with APP metabolism. Antagonizing effects on NMDA receptors and potassium currents may contribute to the neuroprotection as well. It is also possible that the non-catalytic function of AChE is involved in neuroprotective effects of HupA. The therapeutic effects of HupA on AD or VD are probably exerted via a multi-target mechanism. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:71 / 82
页数:12
相关论文
共 50 条
  • [1] Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease
    Lopez, OL
    Becker, JT
    Wisniewski, S
    Saxton, J
    Kaufer, DI
    Dekosky, ST
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 72 (03): : 310 - 314
  • [2] Persistence with Cholinesterase Inhibitor Treatment in Alzheimer's Disease
    Massoud, Fadi
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2013, 40 (05) : 623 - 624
  • [3] Antinociceptive profile of the natural cholinesterase inhibitor huperzine A
    Galeotti, N
    Ghelardini, C
    Mannelli, LD
    Bartolini, A
    DRUG DEVELOPMENT RESEARCH, 2001, 54 (01) : 19 - 26
  • [4] Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer's Disease
    Friedli, Maria Jesus
    Inestrosa, Nibaldo C.
    MOLECULES, 2021, 26 (21):
  • [5] Treatment of Alzheimer's Disease with a Cholinesterase Inhibitor Combined with Antioxidants
    Cornelli, Umberto
    NEURODEGENERATIVE DISEASES, 2010, 7 (1-3) : 193 - 202
  • [6] Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease
    Starr, John M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (05) : 800 - 801
  • [7] Initiating and monitoring cholinesterase inhibitor treatment for Alzheimer's disease
    Swanwick, GRJ
    Lawlor, BA
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 1999, 14 (04) : 244 - 248
  • [8] Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease
    Connelly, PJ
    Prentice, NP
    Fowler, KG
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (03): : 320 - 324
  • [9] A new cholinesterase inhibitor in the symptomatic treatment of Alzheimer's disease
    Solignac, M
    PRESSE MEDICALE, 1998, 27 (33): : 1711 - 1711
  • [10] Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis
    Wang, Bai-song
    Wang, Hao
    Wei, Zhao-hui
    Song, Yan-yan
    Zhang, Lu
    Chen, Hong-zhuan
    JOURNAL OF NEURAL TRANSMISSION, 2009, 116 (04) : 457 - 465